Media Center Investor Relations Overview Newsroom Press Releases Company Statements InBriefs Media Center Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Event Details American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Oct 24 - Oct 28, 2024 Supporting Materials ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB
American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Oct 24 - Oct 28, 2024 Supporting Materials ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB
ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB
ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB
ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB
ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB
ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB
ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB
